Comparative Study of JPB898 and Nivolumab in Combination with Ipilimumab for Advanced Unresectable/Metastatic Melanoma

The primary objective of this study is to evaluate the **pharmacokinetics**, efficacy, safety, and immunogenicity of JPB898, a proposed biosimilar to nivolumab, in combination with Yervoy® in patients with advanced (unresectable/metastatic) **melanoma**. This evaluation is crucial to demonstrate the similarity of JPB898 to the reference product, Opdivo®, which is important for ensuring that patients have access to effective and safe treatment options. The study aims to provide comprehensive data on the biosimilar's performance in comparison to the established treatment regimen.

The clinical trial involves a total of **511 participants** diagnosed with **advanced (unresectable/metastatic) melanoma**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The general health status of the participants is not specified, nor are any lifestyle considerations such as diet, physical activity, or habits. The trial aims to gather data on this specific patient group, but further details regarding the main objective of the study are not disclosed.

The clinical trial is designed to evaluate the **similarity** of JPB898, a proposed biosimilar to nivolumab, in combination with Yervoy® compared to Opdivo® in patients with **advanced (unresectable/metastatic) melanoma**. This study is structured as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thereby minimizing bias. The trial is expected to commence recruitment on August 30, 2024, and is projected to conclude by October 7, 2027, encompassing a comprehensive duration to assess the primary and secondary endpoints effectively.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits to monitor efficacy, safety, and **immunogenicity**. These visits will include assessments such as physical examinations, laboratory tests, and imaging studies as required by the protocol. The end-of-study visit will mark the completion of the participant's involvement, where final evaluations will be conducted to gather conclusive data on the treatment's impact.

The expected length of participant involvement will vary depending on individual response and tolerance to the treatment, but it is anticipated to span the entire duration of the trial unless early termination criteria are met. Conditions that may lead to early withdrawal from the study include adverse events, disease progression, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical standards and regulatory requirements, ensuring the safety and well-being of all participants throughout the study period.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under phase 5, indicating a focus on post-marketing surveillance to gather additional information on the drug's effectiveness and safety in a larger population. The estimated recruitment start date is August 30, 2024, with an anticipated end date of October 7, 2027. Efficacy assessments will be conducted at predetermined intervals throughout the trial duration, utilizing standardized methods to ensure consistency and reliability of the data collected. The specific parameters or endpoints for evaluating efficacy, as well as the tools or instruments involved, are not detailed in the available information. The trial will adhere to rigorous protocols to ensure the validity and accuracy of the efficacy data collected.